AnaptysBio (ANAB) PT Lowered to $20 at Truist Securities

Truist Securities analyst John Lee lowered the price target on AnaptysBio (NASDAQ: ANAB) to $20.00 (from $30.00) while maintaining a Hold rating.

The analyst commented: "We are updating our ANAB model to reflect the following: We're removing ANB032 in AD from our SOTP valuation of ANAB due to recent Ph2b trial failure; Lowering our estimates for imsidolimab as ANAB continue to search for a partner to take the program forward; Our rosnilimab estimates in RA remain unchanged."

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
• Beike (BEKE) PT Raised to $23 at Morgan Stanley